Description

QuidelOrtho’s Hidden Growth Bet: LEX Diagnostics And VITROS 450 Take Center Stage!

QuidelOrtho Corporation reported first quarter 2026 results marked by several notable challenges alongside ongoing strategic initiatives meant to position the company for sustainable growth. Total revenue for the quarter reached $620 million, with non-respiratory revenue accounting for the majority at $552 million. However, the company experienced an 8% decline in its laboratories segment revenues, attributed primarily to a softer respiratory season and the termination of a joint business agreement with Grifols, which negatively impacted comparative results. Respiratory revenue was significantly lower, at $68 million, reflecting an approximately 30% decline in influenza-like illness (ILI) visits in the U.S. during the quarter, a trend consistent across the industry. While testing protocols and market share remained stable, this milder and shorter respiratory season produced lower demand for QuidelOrtho’s respiratory products.